Jorge Santander, MD
Family Medicine · Miami, FLNPI 1467499285
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 26.0% of the total. Reporting peaked in 2019 at $903 and has fallen 78.7% since, to $192 in 2025.
Across 72 payments — averaging $31.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$580
- AbbVie$577
- AstraZeneca$186
- Biohaven Pharmaceutical Holding Company Ltd.$163
- Amarin Pharma, Inc.$147
- Johnson & Johnson$139
- plus $441 from 11 others
Across 807 payments — averaging $2589.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seqirus USA Inc$1.1M
- Astrazeneca UK Limited$412K
- AstraZeneca$285K
- Padagis US LLC$176K
- Perrigo Company PLC$74K
- Journey Medical Corporation$41K
- plus $7K from 2 others
What the payments were for
- Food & beverage$2,21799%
- Gifts$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 5 | $580 |
| AbbVie(2 entities) | 35 | $577 |
| AstraZeneca | 10 | $186 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $163 |
| Amarin Pharma, Inc. | 2 | $147 |
| Johnson & Johnson | 2 | $139 |
| Exact Sciences | 1 | $114 |
| Lilly USA, LLC | 2 | $90 |
| GSK | 5 | $81 |
| Cipher Pharmaceuticals US LLC | 1 | $26 |
| Pfizer | 1 | $24 |
| Novo Nordisk | 1 | $24 |
| Abbott | 1 | $23 |
| Ascend Therapeutics US, LLC | 1 | $16 |
| Merck | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRALUENT$484
- NURTEC ODT$141
- Vascepa$134
- VRAYLAR$125
- XARELTO$122
- The Cologuard Plus Collection Kit$114
How this compares
$2,233 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 72 | $69,874 |
| FarxigaDapagliflozin Propanediol | 67 | $56,543 |
| JanuviaSitagliptin Phosphate | 38 | $43,454 |
| JardianceEmpagliflozin | 38 | $42,152 |
| EliquisApixaban | 31 | $37,168 |
| EntrestoSacubitril/Valsartan | 21 | $20,823 |
| VascepaIcosapent Ethyl | 27 | $18,479 |
| MounjaroTirzepatide | 17 | $18,140 |
| XareltoRivaroxaban | 11 | $16,399 |
| Restasis MultidoseCyclosporine | 13 | $8,359 |
| InvokametCanagliflozin/Metformin Hcl | 12 | $7,058 |
| Diclofenac Sodium | 141 | $6,043 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,673 |
| Acyclovir | 22 | $3,910 |
| LumiganBimatoprost | 11 | $3,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $24 | $69,87472 claims |
| AstraZenecaFarxiga, Symbicort | $186 | $59,05278 claims |
| MerckJanuvia | $16 | $43,45438 claims |
| PfizerEliquis | $24 | $37,16831 claims |
| Johnson & JohnsonXarelto, Invokamet | $139 | $23,45723 claims |
| Lilly USA, LLCMounjaro, Humalog | $90 | $20,42835 claims |
| AbbVieRestasis Multidose, Lumigan, Synthroid | $577 | $15,67451 claims |
| GSKBreo Ellipta | $81 | $4,67312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Miami
- Clifford KinderMiami$75K
- Robert GoubeauxMiami$67K
- Vanessa RojasMiami$50K
- Michelle PowellMiami$34K
- Ana EloseguiMiami$32K
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.